Clinical Trial

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04 -> 2026-09-30 2026-06-11
minor Completion pushed: 2026-04 -> 2026-09-30 2026-06-11
Trial Details
NCT Number NCT04332367
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Non-small Cell Lung Cancer
Enrollment 59 participants
Start Date 2020-08-01
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-10